21 Mar 2022 07:00
Sensyne Health plc
("Sensyne" or the "Company")
Rule 2.9 Announcement
Oxford, U.K. - 21 March 2022: Sensyne Health plc (LSE:SENS) ("Sensyne" or the "Company") announces, for the purposes of Rule 2.9 of the City Code on Takeovers and Mergers, that, following the admission of 1,428,571 New Ordinary Shares today, it will have in issue 166,227,710 ordinary shares of ten pence nominal value each.
The International Securities Identification Number ("ISIN") code for the shares is GB00BYV3J755.
-ENDS-
Notes for editors:
About Sensyne Health: https://www.sensynehealth.com/
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Contact details:
Sensyne Health |
|
| |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer Dr Richard Pye, Chief Financial Officer | +44 (0) 330 058 1845 |
| |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
| |
Dr Christopher Golden James Steel
|
|
| |
Liberum (Joint Broker) |
| ||
Phil Walker William Hall | + 44 (0) 20 3100 2000 | ||
Consilium Strategic Communications |
| ||
Mary-Jane Elliott Jessica Hodgson CSCSensynehealth@consilium-comms.com | +44 (0) 7780 600290 | ||
SternIR |
| ||
Julie Seidel Julie.seidel@sternir.com | +1 (212) 362 1200 | ||